Sustained remission and reversal of end-organ dysfunction in a patient with anaplastic myeloma

This publication has 10 references indexed in Scilit:

• Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432
  Clinical Cancer Research, 2012
• Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma
  Blood, 2010
• Cyclophosphamide and cancer: golden anniversary
  Nature Reviews Clinical Oncology, 2009
• Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
  Leukemia, 2009
• Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma
  Journal of Clinical Oncology, 2008
• Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
  New England Journal of Medicine, 2008
• RELATIVE CONTRIBUTIONS OF THE FIVE MAJOR HUMAN CYTOCHROMES P450, 1A2, 2C9, 2C19, 2D6, AND 3A4, TO THE HEPATIC METABOLISM OF THE PROTEASOME INHIBITOR BORTEZOMIB
  Drug Metabolism and Disposition, 2005
• Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
  New England Journal of Medicine, 2005
• Bortezomib-Induced Severe Hepatitis in Multiple Myeloma
  Archives of internal medicine (1960), 2005
• Anaplastic myeloma with massive extramedullar involvement: Report of two cases
  Cancer, 1983